COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7013e3 · Cited by 707

Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021

Tenforde, M. W., Olson, S. M., Self, W. H., Talbot, H. K., Lindsell, C. J., Steingrub, J. S., Shapiro, N. I., Ginde, A. A., Douin, D. J., Prekker, M. E., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7018e1 · Cited by 286

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021

Wallace, M. M., Woodworth, K. R., Gargano, J. W., Scobie, H. M., Blain, A. E., Moulia, D., Chamberland, M. E., Reisman, N., Hadler, S. C., MacNeil, J. R., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7020e1 · Cited by 141

Rapid, Sensitive, Full-Genome Sequencing of Severe Acute Respiratory Syndrome Coronavirus 2

Paden, C. R., Tao, Y., Queen, K. J., Zhang, J., Li, Y., Uehara, A., & Tong, S. (2020) · Emerging infectious diseases · doi:10.3201/eid2610.201800 · Cited by 135

Impact of the Coronavirus Disease 2019 (COVID-19) Vaccine on Asymptomatic Infection Among Patients Undergoing Preprocedural COVID-19 Molecular Screening

Tande, A. J., Pollock, B. D., Shah, N. D., Farrugia, G., Virk, A., Swift, M., Breeher, L., Binnicker, M., & Berbari, E. F. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab229 · Cited by 120

Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel

Swift, M. D., Breeher, L. E., Tande, A. J., Tommaso, C. P., Hainy, C. M., Chu, H., Murad, M. H., Berbari, E. F., & Virk, A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab361 · Cited by 98

Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity

Tenforde, M. W., Self, W. H., Adams, K., Gaglani, M., Ginde, A. A., McNeal, T., Ghamande, S., Douin, D. J., Talbot, H. K., Casey, J. D., et al. (2021) · JAMA · doi:10.1001/jama.2021.19499 · Cited by 633

Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2

Puhach, O., Adea, K., Hulo, N., Sattonnet‐Roche, P., Genecand, C., Iten, A., Jacquérioz, F., Kaiser, L., Vetter, P., Eckerle, I., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01816-0 · Cited by 369

Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study

Chia, P. Y., Ong, S. W. X., Chiew, C. J., Ang, L. W., Chavatte, J., Mak, T. M., Cui, L., Kalimuddin, S., Chia, W. N., Tan, C. W., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.010 · Cited by 328

Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US

Sun, J., Zheng, Q., Madhira, V., Olex, A. L., Anzalone, A. J., Vinson, A. J., Singh, J. A., French, E., Abraham, A. G., Mathew, J., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.7024 · Cited by 257

SARS-CoV-2 vaccine protection and deaths among US veterans during 2021

Cohn, B. A., Cirillo, P. M., Murphy, C. C., Krigbaum, N. Y., & Wallace, A. W. (2021) · Science · doi:10.1126/science.abm0620 · Cited by 233

Sex Differences in Immunity to Viral Infections

Jacobsen, H., & Klein, S. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.720952 · Cited by 246

Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients

Qin, C. X., Moore, L. W., Anjan, S., Rahamimov, R., Sifri, C. D., Ali, N. M., Morales, M. K., Tsapepas, D. S., Bašić‐Jukić, N., Miller, R. A., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003907 · Cited by 155

Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas

Christensen, P. A., Olsen, R. J., Long, S. W., Subedi, S., Davis, J. J., Hodjat, P., Walley, D. R., Kinskey, J. C., Saavedra, M. O., Pruitt, L., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.10.019 · Cited by 129

Increased risk for COVID ‐19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021

Wang, L., Wang, Q., Davis, P. B., Volkow, N. D., & Xu, R. (2021) · World Psychiatry · doi:10.1002/wps.20921 · Cited by 129

SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status — Los Angeles County, California, May 1–July 25, 2021

Griffin, J. B., Haddix, M., Danza, P., Fisher, R., Koo, T. H., Traub, E., Gounder, P., Jarashow, C., & Balter, S. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7034e5 · Cited by 125

COVID-19 reinfections among naturally infected and vaccinated individuals

Rahman, S., Rahman, M. M., Miah, M., Begum, M. N., Sarmin, M., Mahfuz, M., Hossain, M. E., Rahman, M. Z., Chisti, M. J., Ahmed, T., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-05325-5 · Cited by 111

Sexual dimorphism in COVID-19: potential clinical and public health implications

Bechmann, N., Barthel, A., Schedl, A., Herzig, S., Varga, Z., Gebhard, C., Mayr, M., Hantel, C., Beuschlein, F., Wolfrum, C., et al. (2022) · Publikationen an der Universität Bielefeld (Universität Bielefeld) · Cited by 110

Sexual dimorphism in COVID-19: potential clinical and public health implications

Bechmann, N., Barthel, A., Schedl, A., Herzig, S., Varga, Z., Gebhard, C., Mayr, M., Hantel, C., Beuschlein, F., Wolfrum, C., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00346-6 · Cited by 123

Quantitative SARS-CoV-2 Viral-Load Curves in Paired Saliva Samples and Nasal Swabs Inform Appropriate Respiratory Sampling Site and Analytical Test Sensitivity Required for Earliest Viral Detection

Savela, E. S., Winnett, A. V., Romano, A. E., Porter, M. K., Shelby, N., Akana, R., Ji, J., Cooper, M. M., Schlenker, N. W., Reyes, J. A., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.01785-21 · Cited by 112

Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples

Bates, T. A., Leier, H. C., Lyski, Z. L., Goodman, J. R., Curlin, M. E., Messer, W. B., & Tafesse, F. G. (2021) · JAMA · doi:10.1001/jama.2021.11656 · Cited by 99

Clinical Characterization and Genomic Analysis of Samples from COVID-19 Breakthrough Infections during the Second Wave among the Various States of India

Gupta, N., Kaur, H., Yadav, P., Mukhopadhyay, L., Sahay, R., Kumar, A., Nyayanit, D. A., Shete, A., Patil, S., Majumdar, T., et al. (2021) · Viruses · doi:10.3390/v13091782 · Cited by 67

Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021

Wang, W. J., Kaelber, D. C., Xu, R., & Berger, N. A. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.1096 · Cited by 94

Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States

Coburn, S. B., Humes, E., Lang, R., Stewart, C., Hogan, B., Gebo, K. A., Napravnik, S., Edwards, J. K., Browne, L., Park, L. S., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.15934 · Cited by 93

COVID-19 Mortality Risk Correlates Inversely with Vitamin D3 Status, and a Mortality Rate Close to Zero Could Theoretically Be Achieved at 50 ng/mL 25(OH)D3: Results of a Systematic Review and Meta-Analysis

Borsche, L., Glauner, B., & von Mendel, J. (2021) · Nutrients · doi:10.3390/nu13103596 · Cited by 91

Recurrent neural network models (CovRNN) for predicting outcomes of patients with COVID-19 on admission to hospital: model development and validation using electronic health record data

Rasmy, L., Nigo, M., Kannadath, B. S., Xie, Z., Mao, B., Patel, K., Zhou, Y., Zhang, W., Ross, A., Xu, H., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00049-8 · Cited by 90

Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections

Abu-Raddad, L. J., Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Hasan, M. R., Yassine, H. M., Benslimane, F. M., Al-Khatib, H. A., Kanaani, Z. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28199-7 · Cited by 80

COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research

Wang, L., Kaelber, D. C., Xu, R., & Berger, N. A. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100931 · Cited by 80

Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases

Cook, C., Patel, N. J., D’Silva, K. M., Hsu, T. Y. T., DiIorio, M. A., Prisco, L. C., Martin, L. W., Vanni, K. M. M., Zaccardelli, A., Todd, D. J., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221326 · Cited by 78

COVID-19: stigmatising the unvaccinated is not justified

Kampf, G. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02243-1 · Cited by 75

Reported Adverse Effects and Attitudes among Arab Populations Following COVID-19 Vaccination: A Large-Scale Multinational Study Implementing Machine Learning Tools in Predicting Post-Vaccination Adverse Effects Based on Predisposing Factors

Hatmal, M. M., Al-Hatamleh, M. A. I., Olaimat, A. N., Mohamud, R., Fawaz, M. A., Kateeb, E. T., Alkhairy, O. K., Tayyem, R., Lounis, M., Al‐Raeei, M., et al. (2022) · Vaccines · doi:10.3390/vaccines10030366 · Cited by 73

Risk Factors Associated With SARS-CoV-2 Breakthrough Infections in Fully mRNA-Vaccinated Individuals: Retrospective Analysis

Liu, C., Lee, J., Ta, C., Soroush, A., Rogers, J. R., Kim, J. H., Natarajan, K., Zucker, J. E., Perl, Y., & Weng, C. (2022) · JMIR Public Health and Surveillance · doi:10.2196/35311 · Cited by 69

Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease

Lynch, S. M., Guo, G., Gibson, D. S., Bjourson, A. J., & Singh, T. (2021) · Cells · doi:10.3390/cells10123367 · Cited by 70

SARS-CoV-2 variants, immune escape, and countermeasures

Zhang, Y., Zhang, H. C., & Zhang, W. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0906-x · Cited by 72

Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers

Shamier, M. C., Tostmann, A., Bogers, S., de Wilde, J., IJpelaar, J., van der Kleij, W. A., de Jager, H., Haagmans, B. L., Molenkamp, R., Oude Munnink, B. B., et al. (2021) · doi:10.1101/2021.08.20.21262158 · Cited by 56

Vaccine Hesitancy towards COVID-19 Vaccination: Investigating the Role of Information Sources through a Mediation Analysis

Reno, C., Maietti, E., Valerio, Z. D., Montalti, M., Fantini, M. P., & Gori, D. (2021) · Infectious Disease Reports · doi:10.3390/idr13030066 · Cited by 63

SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19

Ravichandran, S., Tang, J., Grubbs, G., Lee, Y., Pourhashemi, S., Hussaini, L., Lapp, S. A., Jerris, R. C., Singh, V., Chahroudi, A., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01051-8 · Cited by 60

Multiple COVID-19 Waves and Vaccination Effectiveness in the United States

Lin, L., Zhao, Y., Chen, B., & He, D. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19042282 · Cited by 62

College openings in the United States increase mobility and COVID-19 incidence

Andersen, M. S., Bento, A. I., Basu, A., Marsicano, C. R., & Simon, K. I. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272820 · Cited by 61

Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States

Li, R., Liu, H., Fairley, C. K., Zou, Z., Xie, L., Li, X., Shen, M., Li, Y., & Zhang, L. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.029 · Cited by 60

Factors associated with decision making on COVID-19 vaccine acceptance among college students in South Carolina

Tam, C. C., Qiao, S., & Li, X. (2021) · Psychology Health & Medicine · doi:10.1080/13548506.2021.1983185 · Cited by 58

COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents

Canaday, D. H., Oyebanji, O. A., White, E. M., Keresztesy, D., Payne, M., Wilk, D. J., Carias, L. L., Aung, H., Denis, K. S., Sheehan, M. L., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104066 · Cited by 60

Postvaccination COVID‐19 infection is associated with reduced mortality in patients with cirrhosis

John, B. V., Deng, Y., Schwartz, K. B., Taddei, T. H., Kaplan, D. E., Martin, P. B., Chao, H., & Dahman, B. A. (2022) · Hepatology · doi:10.1002/hep.32337 · Cited by 56

Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City

Duerr, R., Dimartino, D., Marier, C., Zappile, P., Wang, G., Lighter, J., Elbel, B. D., Troxel, A. B., & Heguy, A. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152702 · Cited by 53

Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India

Behera, P., Singh, A. K., Subba, S. H., Arjun, M. C., Sahu, D. P., Chandanshive, P. D., Pradhan, S. K., Parida, S. P., Mishra, A., Patro, B. K., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2034456 · Cited by 51

Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era

Wang, S. Y., Juthani, P. V., Borges, K. A., Shallow, M., Gupta, A. K., Price, C. C., Won, C. H. J., & Chun, H. J. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00306-2 · Cited by 48

Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections

Ahmad, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.742167 · Cited by 46

Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models

Zhou, R., Wang, P., Wong, Y.-C., Xu, H., Lau, S.-Y., Liu, L., Mok, B. W.-Y., Peng, Q., Liu, N., Woo, K. F., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103762 · Cited by 50

Variants of Concern Are Overrepresented Among Postvaccination Breakthrough Infections of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Washington State

McEwen, A. E., Cohen, S., Bryson‐Cahn, C., Liu, C., Pergam, S. A., Lynch, J. B., Schippers, A., Strand, K., Whimbey, E. E., Mani, N. S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab581 · Cited by 51

Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California

Servellita, V., Morris, M. K., Sotomayor-González, A., Gliwa, A. S., Torres, E., Brazer, N., Zhou, A. Y., Hernandez, K., Sankaran, M., Wang, B., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01041-4 · Cited by 46

COVID‐19 breakthrough infections and hospitalizations among vaccinated patients with dementia in the United States between December 2020 and August 2021

Wang, L., Davis, P. B., Kaelber, D. C., & Xu, R. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12669 · Cited by 46

SARS‐CoV‐2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVID‐19 Vaccination

Moon, A. M., Webb, G. J., García‐Juárez, I., Kulkarni, A. V., Adalı, G., Wong, D., Lusina, B., Dalekos, G. Ν., Masson, S., Shore, B. M., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1853 · Cited by 45

Potential Genes Associated with COVID-19 and Comorbidity

Feng, S., Song, F.-Q., Guo, W., Tan, J., Zhang, X., Qiao, F., Guo, J., Zhang, L., & Jia, X. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.67815 · Cited by 44

Breakthrough Infections of SARS-CoV-2 Gamma Variant in Fully Vaccinated Gold Miners, French Guiana, 2021

Vignier, N., Bérot, V., Bonnave, N., Peugny, S., Ballet, M., Jacoud, E., Michaud, C., Gaillet, M., Djossou, F., Blanchet, D., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2710.211427 · Cited by 44

Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US

Lang, R., Humes, E., Coburn, S. B., Horberg, M. A., Fathi, L., Watson, E. S., Jefferson, C. R., Park, L. S., Gordon, K. S., Akgün, K. M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.36397 · Cited by 43

Monoclonal antibody therapies in the management of SARS-CoV-2 infection

Rey, E. M., Choi, D., Kim, S., Yoon, S., & Săndulescu, O. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2030310 · Cited by 46

Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine

Rzymski, P., Pazgan−Simon, M., Simon, K. A., Łapiński, T. W., Zarębska‐Michaluk, D., Szczepańska, B., Chojnicki, M., Mozer‐Lisewska, I., & Flisiak, R. (2021) · Vaccines · doi:10.3390/vaccines9070781 · Cited by 42

Will vaccine-derived protective immunity curtail COVID-19 variants in the US?

Mancuso, M., Eikenberry, S. E., & Gumel, A. B. (2021) · Infectious Disease Modelling · doi:10.1016/j.idm.2021.08.008 · Cited by 42

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

Ma, H., Zhang, X., Zheng, P., Dube, P. H., Zeng, W., Chen, S., Cheng, Q., Yang, Y., Wu, Y., Zhou, J., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00700-3 · Cited by 42

Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention

Li, Y.-R., Dunn, Z. S., Garcia, G., Carmona, C., Zhou, Y., Lee, D. P. H., Yu, J., Huang, J., Kim, J. T., Arumugaswami, V., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02787-2 · Cited by 39

Elucidating causes of COVID-19 infection and related deaths after vaccination

Jain, V. K., Iyengar, K. P., & Ish, P. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102212 · Cited by 39

Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge

Bierle, D. M., Ganesh, R., & Razonable, R. R. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.105026 · Cited by 40

Breakthrough COVID-19 Infections After mRNA Vaccination in Solid Organ Transplant Recipients in Miami, Florida

Anjan, S., Natori, Y., Betances, A. F., Agritelley, M. S., Mattiazzi, A. D., Arosemena, L. R., Andrews, D. M., Simkins, J., Guerra, G., & Abbo, L. M. (2021) · Transplantation · doi:10.1097/tp.0000000000003902 · Cited by 38

Characteristics of COVID-19 Breakthrough Infections among Vaccinated Individuals and Associated Risk Factors: A Systematic Review

Gopinath, S., Ishak, A., Dhawan, N., Poudel, S., Shrestha, P. S., Singh, P., Xie, E., Tahir, P., Marzaban, S., Michel, J., et al. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7050081 · Cited by 39

Higher COVID-19 Vaccination Rates Are Associated with Lower COVID-19 Mortality: A Global Analysis

Hoxha, I. S., Agahi, R., Bimbashi, A., Aliu, M., Raka, L., Bajraktari, I., Beqiri, P., & Adams, L. V. (2022) · Vaccines · doi:10.3390/vaccines11010074 · Cited by 37

Variants of concern responsible for SARS‐CoV‐2 vaccine breakthrough infections from India

Singh, U. B., Rophina, M., Chaudhry, R., Senthivel, V., Bala, K., Bhoyar, R. C., Jolly, B., Jamshed, N., Imran, M., Gupta, R., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27461 · Cited by 35

Improved SARS-CoV-2 main protease high-throughput screening assay using a 5-carboxyfluorescein substrate

Legare, S., Heide, F., Bailey-Elkin, B. A., & Stetefeld, J. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101739 · Cited by 35

Blaming the unvaccinated during the COVID-19 pandemic: the roles of political ideology and risk perceptions in the USA

Graso, M., Aquino, K. F., Chen, F. X., & Bardosh, K. (2023) · Journal of Medical Ethics · doi:10.1136/jme-2022-108825 · Cited by 36

A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge

Zhou, B., Zhou, R., Tang, B., Chan, J. F., Luo, M., Peng, Q., Yuan, S., Liu, H., Mok, B. W.-Y., Chen, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31259-7 · Cited by 32

Vaccine‐breakthrough infection by the SARS‐CoV‐2 omicron variant elicits broadly cross‐reactive immune responses

Zhou, R., To, K. K., Peng, Q., Chan, J. M., Huang, H., Yang, D., Lam, B. H. S., Chuang, V. W., Cai, J., Liu, N., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.720 · Cited by 33

The intestinal microbiota and improving the efficacy of COVID-19 vaccinations

Chen, J., Vitetta, L., Henson, J. D., & Hall, S. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104850 · Cited by 32

Mutational dynamics of SARS-CoV-2: Impact on future COVID-19 vaccine strategies

Faraji, N., Zeinali, T., Joukar, F., Aleali, M. S., Eslami, N., Shenagari, M., & Mansour‐Ghanaei, F. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30208 · Cited by 32

Trajectory of Growth of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in Houston, Texas, January through May 2021, Based on 12,476 Genome Sequences

Olsen, R. J., Christensen, P. A., Long, S. W., Subedi, S., Hodjat, P., Olson, R., Nguyen, M., Davis, J. J., Yerramilli, P., Saavedra, M. O., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.07.002 · Cited by 30

Breakthrough SARS‐CoV‐2 infections among BBV‐152 (COVAXIN®) and AZD1222 (COVISHIELDTM) recipients: Report from the eastern state of India

Dash, G. C., Subhadra, S., Turuk, J., Parai, D., Rath, S., Sabat, J., Rout, U. K., Kanungo, S., Choudhary, H. R., Nanda, R. R., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27382 · Cited by 31

Cultural and Social Factors in Care Delivery Among African American Caregivers of Persons With Dementia: A Scoping Review

Udoh, I. I., & Tinofirei, C. (2023) · Gerontology and Geriatric Medicine · doi:10.1177/23337214231152002 · Cited by 31

Evaluating cepharanthine analogues as natural drugs against SARS‐CoV‐2

Hijikata, A., Shionyu‐Mitsuyama, C., Nakae, S., Shionyu, M., Ota, M., Kanaya, S., Hirokawa, T., Nakajima, S., Watashi, K., & Shirai, T. (2021) · FEBS Open Bio · doi:10.1002/2211-5463.13337 · Cited by 30

Suspected Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Reinfections: Incidence, Predictors, and Healthcare Use Among Patients at 238 US Healthcare Facilities, 1 June 2020 to 28 February 2021

Lawandi, A., Warner, S., Sun, J., Demirkale, C. Y., Danner, R. L., Klompas, M., Gundlapalli, A. V., Datta, D., Harris, A. M., Morris, S. B., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab671 · Cited by 29

Disparities In County COVID-19 Vaccination Rates Linked To Disadvantage And Hesitancy

Crane, M. A., Faden, R., & Romley, J. A. (2021) · Health Affairs · doi:10.1377/hlthaff.2021.01092 · Cited by 28

Licorice (Glycyrrhiza glabra) Extracts-Suitable Pharmacological Interventions for COVID-19? A Review

Abraham, J., & Florentine, S. K. (2021) · Plants · doi:10.3390/plants10122600 · Cited by 30

SARS-CoV-2 reinfection after previous infection and vaccine breakthrough infection through the second wave of pandemic in India: An observational study

Dhumal, S. B., Patil, A., More, A. N., Kamtalwar, S., Joshi, A. D., Gokarn, A. G., Mirgh, S. P., Thatikonda, P., Bhat, P., Murthy, V., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.02.037 · Cited by 27

Prevalence of Antibodies to SARS-CoV-2 Following Natural Infection and Vaccination in Irish Hospital Healthcare Workers: Changing Epidemiology as the Pandemic Progresses

Allen, N., Brady, M., Riain, U. N., Conlon, N. P., Domegan, L. M., Martín, A. I. C., Walsh, C., Doherty, L., Higgins, E., Kerr, C., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.758118 · Cited by 29

A non-linear differential equation model of COVID-19 and seasonal influenza co-infection dynamics under vaccination strategy and immunity waning

Rabiu, M., Peter, O. J., & Oguntolu, F. A. (2023) · Healthcare Analytics · doi:10.1016/j.health.2023.100240 · Cited by 34

Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil

Estofolete, C. F., Banho, C. Á., Campos, G. R. F., Marques, B. D. C., Sacchetto, L., Ullmann, L. S., Possebon, F. S., Machado, L. F., Syrio, J. D., Araújo, J. P., et al. (2021) · Viruses · doi:10.3390/v13071237 · Cited by 27

Transmission and containment of the SARS-CoV-2 Delta variant of concern in Guangzhou, China: A population-based study

Li, L., Han, Z., Qin, P., Liu, W., Zhou, Y., Chen, Z.-Q., Li, K., Xie, C., Ma, Y., Wang, H., et al. (2022) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0010048 · Cited by 27

Coronavirus Disease 2019 Vaccine-Breakthrough Infections Requiring Hospitalization in Mayo Clinic Florida Through August 2021

Bosch, W., Cowart, J. B., Bhakta, S., Carter, R. E., Wadei, H. M., Shah, S. Z., Sanghavi, D., Pollock, B. D., Neville, M. R., Oman, S. P., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab932 · Cited by 26

Assessing COVID-19 Prevention Strategies to Permit the Safe Opening of Residential Colleges in Fall 2021

Paltiel, A. D., & Schwartz, J. L. (2021) · Annals of Internal Medicine · doi:10.7326/m21-2965 · Cited by 26

Effectiveness of Heterologous Coronavirus Disease 2019 (COVID-19) Vaccine Booster Dosing in Brazilian Healthcare Workers, 2021

Marra, A. R., Miraglia, J. L., Malheiros, D. T., Guozhang, Y., Teich, V., Victor, E. D. S., Pinho, J. R. R., Cypriano, A. S., Vieira, L. W., Polonio, M., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac430 · Cited by 24

The pH Dependence of Niclosamide Solubility, Dissolution, and Morphology: Motivation for Potentially Universal Mucin-Penetrating Nasal and Throat Sprays for COVID19, its Variants and other Viral Infections

Needham, D. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03112-x · Cited by 25

At-home testing to mitigate community transmission of SARS-CoV-2: protocol for a public health intervention with a nested prospective cohort study

Ciccone, E. J., Conserve, D. F., Dave, G., Hornik, C. P. V., Kuhn, M. L., Herling, J. L., Song, M., Alston, S. M., Singler, L., Schmidt, M. D., et al. (2021) · BMC Public Health · doi:10.1186/s12889-021-12007-w · Cited by 25

Human coronaviruses: The emergence of SARS-CoV-2 and management of COVID-19

Solomon, M., & Liang, C. (2022) · Virus Research · doi:10.1016/j.virusres.2022.198882 · Cited by 25

Association Between Vaccination Status and Outcomes in Patients Admitted to the ICU With COVID-19*

van Diepen, S., McAlister, F. A., Chu, L. M., Youngson, E. R. E., Kaul, P., & Kadri, S. S. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000005928 · Cited by 26

IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population

Guzmán-Martínez, O., Guardado, K., de Guevara, E. L., Navarro, S. M., Hernández, C., Zenteno‐Cuevas, R., & Montero, H. (2021) · Vaccines · doi:10.3390/vaccines9090999 · Cited by 26

Hospitalized patients with breakthrough COVID-19: Clinical features and poor outcome predictors

Moreno, Ó., Ribes, I., Boix, V., García, M. Á. M., Otero-Rodríguez, S., Reus, S., Sánchez‐Martínez, R., Ramos, J. M., Chico-Sánchez, P., & Merino, E. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.02.007 · Cited by 23

Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study

Hu, Z., van der Ploeg, K., Chakraborty, S., Arunachalam, P. S., Mori, D. A., Jacobson, K. B., Bonilla, H. F., Parsonnet, J., Andrews, J. R., Holubar, M. K., et al. (2022) · eLife · doi:10.7554/elife.77943 · Cited by 30

Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case

Connor, B. A., Couto-Rodriguez, M., Barrows, J., Gardner, M., Rogova, M., O’Hara, N. B., & Nagy‐Szakal, D. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.07.029 · Cited by 22

Symptomatic post-vaccination SARS-CoV-2 infections in healthcare workers– A multicenter cohort study

Vaishya, R., Sibal, A., Malani, A., Kar, S., Hari Prasad, K., Kiran, S. V., Reddy, S., Kamineni, S., Reddy, S., Reddy, P. A., et al. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102306 · Cited by 22

COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature

Alshanqeeti, S., & Bhargava, A. (2022) · Cureus · doi:10.7759/cureus.26239 · Cited by 21

Stability and inactivation of SARS-CoV-2 on food contact surfaces

Jung, S., Kim, D., Ahn, H., Go, H., Wang, Z., Yeo, D., Woo, S., Seo, Y., Hossain, M. I., Choi, I., et al. (2022) · Food Control · doi:10.1016/j.foodcont.2022.109306 · Cited by 22

Effectiveness and safety of COVID-19 vaccines in patients with diabetes as a factor for vaccine hesitancy

Vasilev, G., Kabakchieva, P., Miteva, D., Batselova, H., & Velikova, T. V. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i9.738 · Cited by 23

Prevalence and predictors of COVID-19 vaccination hesitancy among healthcare workers in Sub-Saharan Africa: A systematic review and meta-analysis

Kigongo, E., Kabunga, A., Tumwesigye, R., Musinguzi, M., Izaruku, R., & Acup, W. (2023) · PLoS ONE · doi:10.1371/journal.pone.0289295 · Cited by 22

Assessment of Machine Learning Techniques in IoT-Based Architecture for the Monitoring and Prediction of COVID-19

Aljumah, A. A. (2021) · Electronics · doi:10.3390/electronics10151834 · Cited by 21

Breakthrough Infections with Multiple Lineages of SARS-CoV-2 Variants Reveals Continued Risk of Severe Disease in Immunosuppressed Patients

Deng, X., Evdokimova, M., O’Brien, A., Rowe, C. L., Clark, N. M., Harrington, A., Reid, G., Uprichard, S. L., & Baker, S. C. (2021) · Viruses · doi:10.3390/v13091743 · Cited by 21

Alpha, Beta, Delta, Omicron, and SARS-CoV-2 Breakthrough Cases: Defining Immunological Mechanisms for Vaccine Waning and Vaccine-Variant Mismatch

Hewins, B., Rahman, M., Bermejo-Martín, J. F., Kelvin, A. A., Richardson, C. D., Rubino, S., Kumar, A., Ndishimye, P., Ostadgavahi, A. T., Mahmud-Al-Rafat, A., et al. (2022) · Frontiers in Virology · doi:10.3389/fviro.2022.849936 · Cited by 21

Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers

Kale, P. R., Gupta, E., Bihari, C., Patel, N., Rooge, S. B., Pandey, A. K., Bajpai, M., Khillan, V., Chattopadhyay, P., Devi, P., et al. (2021) · Vaccines · doi:10.3390/vaccines10010054 · Cited by 20

Clinical characteristics of COVID‐19 in solid organ transplant recipients following COVID‐19 vaccination: A multicenter case series

Saharia, K., Anjan, S., Streit, J. A., Beekmann, S. E., Polgreen, P. M., Kuehnert, M. J., Segev, D. L., Baddley, J. W., Miller, R. A., & the EIN COVID‐19 Study Team (2021) · Transplant Infectious Disease · doi:10.1111/tid.13774 · Cited by 19

Estimating the number of symptomatic SARS-CoV-2 infections among vaccinated individuals in the United States—January–July, 2021

Kugeler, K. J., Williamson, J., Curns, A. T., Healy, J. M., Nolen, L. D., Clark, T. A., Martin, S. W., & Fischer, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264179

Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19

Parums, D. V. (2021) · Medical Science Monitor · doi:10.12659/msm.935624 · Cited by 4

COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate Vaccine Effectiveness

Reynolds, M. W., Xie, Y., Knuth, K. B., Mack, C. D., Brinkley, E., Toovey, S., & Dreyer, N. A. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 1

The impact of vaccination on COVID-19

Shamama, F., Zhamutashvili, M., Dolmazashvili, E., Badridze, N., Gognadze, T., & Sharvadze, L. (2023) · Journal of Biomedical and Medical Sciences · doi:10.51231/2667-9507-2023-002-01-62-66 · Cited by 1

POSC419 Examining the Rate of COVID-19 Breakthrough Infections in Individuals Who Received mRNA Vaccine in the United States

Madge, V. J., Bhardwaj, N., & Mazumder, D. (2022) · Value in Health · doi:10.1016/j.jval.2021.11.1320